Cell Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

TMR's report on the global cell analysis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cell analysis market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell analysis market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cell analysis market.

Market Snapshot
Market Value in 2023	US$ 19 Bn
Market Value in 2031	US$ 42.4 Bn
CAGR	9.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell analysis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell analysis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell analysis market.

The report delves into the competitive landscape of the global cell analysis market. Key players operating in the global cell analysis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell analysis market profiled in this report.

Key Questions Answered in Global Cell Analysis Market Report:

What is the sales/revenue generated by cell analysis across all regions during the forecast period?
What are the opportunities in the global cell analysis market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Cell Analysis Market - Research Objectives and Research Approach

The comprehensive report on the global cell analysis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell analysis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell analysis market.

Product Code: TMRGL12221

1. Preface

1.1. Market Definition and Scope
1.2. Key Research Objectives

2. Assumptions and Research Methodology

3. Market Overview

3.1. Overview
3.2. Market Dynamics
- 3.2.1. Drivers
- 3.2.2. Restraints
- 3.2.3. Opportunities
3.3. Overview on R&D spending of major biotechnology and pharmaceutical companies by therapeutic area
- 3.3.1. Top 15 Origins of Pipeline Drugs
- 3.3.2. Biological versus non-biological drugs as a % of pipeline
- 3.3.3. Ongoing rise of gene and cell therapy

4. Global Cell Analysis Market Analysis and Forecast, by End-user

4.1. Introduction & Definition
4.2. Key Findings/Developments
4.3. Market Value Forecast, by End-user, 2017-2031
- 4.3.1. Biotechnology & Pharmaceutical Companies
- 4.3.2. Academia
- 4.3.3. Cosmetic Industry
- 4.3.4. Contract Research Organizations
- 4.3.5. Contract Development and Manufacturing Organizations

5. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Therapeutic Area

5.1. Introduction & Definition
5.2. Key Findings/Developments
5.3. Market Value Forecast, by Therapeutic Area, 2015-2031
- 5.3.1. Oncology & Immune-oncology
  - 5.3.1.1. Small Molecules
  - 5.3.1.2. Protein-based Therapeutics
  - 5.3.1.3. Cell Therapy
  - 5.3.1.4. Nucleic Acid-based Drugs
- 5.3.2. Cardiovascular & Metabolic Diseases
  - 5.3.2.1. Small Molecules
  - 5.3.2.2. Protein-based Therapeutics
  - 5.3.2.3. Cell Therapy
  - 5.3.2.4. Nucleic Acid-based Drugs
- 5.3.3. Immunology
  - 5.3.3.1. Small Molecules
  - 5.3.3.2. Protein-based Therapeutics
  - 5.3.3.3. Cell Therapy
  - 5.3.3.4. Nucleic Acid-based Drugs
- 5.3.4. Rare Diseases
  - 5.3.4.1. Small Molecules
  - 5.3.4.2. Protein-based Therapeutics
  - 5.3.4.3. Cell Therapy
  - 5.3.4.4. Nucleic Acid-based Drugs
- 5.3.5. Neurological Diseases
  - 5.3.5.1. Small Molecules
  - 5.3.5.2. Protein-based Therapeutics
  - 5.3.5.3. Cell Therapy
  - 5.3.5.4. Nucleic Acid-based Drugs
- 5.3.6. Others
  - 5.3.6.1. Small Molecules
  - 5.3.6.2. Protein-based Therapeutics
  - 5.3.6.3. Cell Therapy
  - 5.3.6.4. Nucleic Acid-based Drugs

6. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Technology

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Technology, 2017-2031
- 6.3.1. Flow Cytometry
- 6.3.2. Image-based Cytometry
- 6.3.3. Biochemical Assays
- 6.3.4. Mass Spectrometry

7. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Workplace, 2017-2031
- 7.3.1. Target Identification
- 7.3.2. Hit Generation & Lead Identification
- 7.3.3. Lead Optimization
- 7.3.4. In Vitro Preclinical Studies
- 7.3.5. In Vivo Preclinical Studies
- 7.3.6. Clinical Studies

8. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Country/Region

8.1. Key Findings
8.2. Market Value Forecast, by Country/Region, 2017-2031
- 8.2.1. U.S.
- 8.2.2. Europe
- 8.2.3. China
- 8.2.4. Rest of the World

9. U.S. Cell Analysis Market Analysis and Forecast

9.1. Introduction
- 9.1.1. Key Findings
9.2. Market Value Forecast, by End-user, 2017-2031
- 9.2.1. Biotechnology & Pharmaceutical Companies
- 9.2.2. Academia
- 9.2.3. Cosmetic Industry
- 9.2.4. Contract Research Organizations
- 9.2.5. Contract Development and Manufacturing Organizations
9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
- 9.3.1. Oncology & Immune-oncology
  - 9.3.1.1. Small Molecules
  - 9.3.1.2. Protein-based Therapeutics
  - 9.3.1.3. Cell Therapy
  - 9.3.1.4. Nucleic Acid-based Drugs
- 9.3.2. Cardiovascular & Metabolic Diseases
  - 9.3.2.1. Small Molecules
  - 9.3.2.2. Protein-based Therapeutics
  - 9.3.2.3. Cell Therapy
  - 9.3.2.4. Nucleic Acid-based Drugs
- 9.3.3. Immunology
  - 9.3.3.1. Small Molecules
  - 9.3.3.2. Protein-based Therapeutics
  - 9.3.3.3. Cell Therapy
  - 9.3.3.4. Nucleic Acid-based Drugs
- 9.3.4. Rare Diseases
  - 9.3.4.1. Small Molecules
  - 9.3.4.2. Protein-based Therapeutics
  - 9.3.4.3. Cell Therapy
  - 9.3.4.4. Nucleic Acid-based Drugs
- 9.3.5. Neurological Diseases
  - 9.3.5.1. Small Molecules
  - 9.3.5.2. Protein-based Therapeutics
  - 9.3.5.3. Cell Therapy
  - 9.3.5.4. Nucleic Acid-based Drugs
- 9.3.6. Others
  - 9.3.6.1. Small Molecules
  - 9.3.6.2. Protein-based Therapeutics
  - 9.3.6.3. Cell Therapy
  - 9.3.6.4. Nucleic Acid-based Drugs
9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
- 9.4.1. Flow Cytometry
- 9.4.2. Image-based Cytometry
- 9.4.3. Biochemical Assays
- 9.4.4. Mass Spectrometry
9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
- 9.5.1. Target Identification
- 9.5.2. Hit Generation & Lead Identification
- 9.5.3. Lead Optimization
- 9.5.4. In Vitro Preclinical Studies
- 9.5.5. In Vivo Preclinical Studies
- 9.5.6. Clinical Studies

10. Europe Cell Analysis Market Analysis and Forecast

10.1. Introduction
- 10.1.1. Key Findings
10.2. Market Value Forecast, by End-user, 2017-2031
- 10.2.1. Biotechnology & Pharmaceutical Companies
- 10.2.2. Academia
- 10.2.3. Cosmetic Industry
- 10.2.4. Contract Research Organizations
- 10.2.5. Contract Development and Manufacturing Organizations
10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
- 10.3.1. Oncology & Immune-oncology
  - 10.3.1.1. Small Molecules
  - 10.3.1.2. Protein-based Therapeutics
  - 10.3.1.3. Cell Therapy
  - 10.3.1.4. Nucleic Acid-based Drugs
- 10.3.2. Cardiovascular & Metabolic Diseases
  - 10.3.2.1. Small Molecules
  - 10.3.2.2. Protein-based Therapeutics
  - 10.3.2.3. Cell Therapy
  - 10.3.2.4. Nucleic Acid-based Drugs
- 10.3.3. Immunology
  - 10.3.3.1. Small Molecules
  - 10.3.3.2. Protein-based Therapeutics
  - 10.3.3.3. Cell Therapy
  - 10.3.3.4. Nucleic Acid-based Drugs
- 10.3.4. Rare Diseases
  - 10.3.4.1. Small Molecules
  - 10.3.4.2. Protein-based Therapeutics
  - 10.3.4.3. Cell Therapy
  - 10.3.4.4. Nucleic Acid-based Drugs
- 10.3.5. Neurological Diseases
  - 10.3.5.1. Small Molecules
  - 10.3.5.2. Protein-based Therapeutics
  - 10.3.5.3. Cell Therapy
  - 10.3.5.4. Nucleic Acid-based Drugs
- 10.3.6. Others
  - 10.3.6.1. Small Molecules
  - 10.3.6.2. Protein-based Therapeutics
  - 10.3.6.3. Cell Therapy
  - 10.3.6.4. Nucleic Acid-based Drugs
10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
- 10.4.1. Flow Cytometry
- 10.4.2. Image-based Cytometry
- 10.4.3. Biochemical Assays
- 10.4.4. Mass Spectrometry
10.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
- 10.5.1. Target Identification
- 10.5.2. Hit Generation & Lead Identification
- 10.5.3. Lead Optimization
- 10.5.4. In Vitro Preclinical Studies
- 10.5.5. In Vivo Preclinical Studies
- 10.5.6. Clinical Studies
10.6. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031
- 10.6.1. EU5
- 10.6.2. U.K.
- 10.6.3. Switzerland
- 10.6.4. Rest of Europe

11. China Cell Analysis Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by End-user, 2017-2031
- 11.2.1. Biotechnology & Pharmaceutical Companies
- 11.2.2. Academia
- 11.2.3. Cosmetic Industry
- 11.2.4. Contract Research Organizations
- 11.2.5. Contract Development and Manufacturing Organizations
11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
- 11.3.1. Oncology & Immune-oncology
  - 11.3.1.1. Small Molecules
  - 11.3.1.2. Protein-based Therapeutics
  - 11.3.1.3. Cell Therapy
  - 11.3.1.4. Nucleic Acid-based Drugs
- 11.3.2. Cardiovascular & Metabolic Diseases
  - 11.3.2.1. Small Molecules
  - 11.3.2.2. Protein-based Therapeutics
  - 11.3.2.3. Cell Therapy
  - 11.3.2.4. Nucleic Acid-based Drugs
- 11.3.3. Immunology
  - 11.3.3.1. Small Molecules
  - 11.3.3.2. Protein-based Therapeutics
  - 11.3.3.3. Cell Therapy
  - 11.3.3.4. Nucleic Acid-based Drugs
- 11.3.4. Rare Diseases
  - 11.3.4.1. Small Molecules
  - 11.3.4.2. Protein-based Therapeutics
  - 11.3.4.3. Cell Therapy
  - 11.3.4.4. Nucleic Acid-based Drugs
- 11.3.5. Neurological Diseases
  - 11.3.5.1. Small Molecules
  - 11.3.5.2. Protein-based Therapeutics
  - 11.3.5.3. Cell Therapy
  - 11.3.5.4. Nucleic Acid-based Drugs
- 11.3.6. Others
  - 11.3.6.1. Small Molecules
  - 11.3.6.2. Protein-based Therapeutics
  - 11.3.6.3. Cell Therapy
  - 11.3.6.4. Nucleic Acid-based Drugs
11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
- 11.4.1. Flow Cytometry
- 11.4.2. Image-based Cytometry
- 11.4.3. Biochemical Assays
- 11.4.4. Mass Spectrometry
11.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
- 11.5.1. Target Identification
- 11.5.2. Hit Generation & Lead Identification
- 11.5.3. Lead Optimization
- 11.5.4. In Vitro Preclinical Studies
- 11.5.5. In Vivo Preclinical Studies
- 11.5.6. Clinical Studies

12. Rest of the World Cell Analysis Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by End-user, 2017-2031
- 12.2.1. Biotechnology & Pharmaceutical Companies
- 12.2.2. Academia
- 12.2.3. Cosmetic Industry
- 12.2.4. Contract Research Organizations
- 12.2.5. Contract Development and Manufacturing Organizations
12.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
- 12.3.1. Oncology & Immune-oncology
  - 12.3.1.1. Small Molecules
  - 12.3.1.2. Protein-based Therapeutics
  - 12.3.1.3. Cell Therapy
  - 12.3.1.4. Nucleic Acid-based Drugs
- 12.3.2. Cardiovascular & Metabolic Diseases
  - 12.3.2.1. Small Molecules
  - 12.3.2.2. Protein-based Therapeutics
  - 12.3.2.3. Cell Therapy
  - 12.3.2.4. Nucleic Acid-based Drugs
- 12.3.3. Immunology
  - 12.3.3.1. Small Molecules
  - 12.3.3.2. Protein-based Therapeutics
  - 12.3.3.3. Cell Therapy
  - 12.3.3.4. Nucleic Acid-based Drugs
- 12.3.4. Rare Diseases
  - 12.3.4.1. Small Molecules
  - 12.3.4.2. Protein-based Therapeutics
  - 12.3.4.3. Cell Therapy
  - 12.3.4.4. Nucleic Acid-based Drugs
- 12.3.5. Neurological Diseases
  - 12.3.5.1. Small Molecules
  - 12.3.5.2. Protein-based Therapeutics
  - 12.3.5.3. Cell Therapy
  - 12.3.5.4. Nucleic Acid-based Drugs
- 12.3.6. Others
  - 12.3.6.1. Small Molecules
  - 12.3.6.2. Protein-based Therapeutics
  - 12.3.6.3. Cell Therapy
  - 12.3.6.4. Nucleic Acid-based Drugs
12.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
- 12.4.1. Flow Cytometry
- 12.4.2. Image-based Cytometry
- 12.4.3. Biochemical Assays
- 12.4.4. Mass Spectrometry
12.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
- 12.5.1. Target Identification
- 12.5.2. Hit Generation & Lead Identification
- 12.5.3. Lead Optimization
- 12.5.4. In Vitro Preclinical Studies
- 12.5.5. In Vivo Preclinical Studies
- 12.5.6. Clinical Studies

Product Code: TMRGL12221

List of Tables

Table 01: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (1/4)
Table 02: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (2/4)
Table 03: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (2/3)
Table 04: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (4/4)
Table 05: Top 15 Origins of Pipeline Drugs
Table 06: Global Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 07: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 08: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 09: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 10: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 11: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 12: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 13: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 14: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 15: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 16: Global Cell Analysis Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 17: U.S. Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 18: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 19: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 20: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 21: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 22: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 23: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 24: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 25: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 26: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 27: Europe Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 28: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 29: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 30: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 31: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 32: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 33: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 34: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 35: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 36: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 37: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 38: China Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 39: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 40: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 41: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 42: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 43: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 44: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 45: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 46: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 47: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 48: Rest of the World Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 49: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 50: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 51: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 52: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 53: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 54: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 55: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 56: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
Table 57: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031

List of Figures

Figure 01: Major R&D spending therapeutic areas, by companies
Figure 02: Biological versus non-biological drugs as a % of pipeline
Figure 03: Ongoing rise of gene and cell therapy
Figure 04: Global Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 05: Global Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 06: Global Cell Analysis Market (US$ Mn), by Biotechnology & Pharmaceutical Companies, 2017-2031
Figure 07: Global Cell Analysis Market (US$ Mn), by Academia, 2017-2031
Figure 08: Global Cell Analysis Market (US$ Mn), by Cosmetic Industry, 2017-2031
Figure 09: Global Cell Analysis Market (US$ Mn), by Contract Research Organizations, 2017-2031
Figure 10: Global Cell Analysis Market (US$ Mn), by Contract Development and Manufacturing Organizations, 2017-2031
Figure 11: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 12: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 13: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Oncology & Immune-oncology, 2017-2031
Figure 14: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Cardiovascular & Metabolic Diseases, 2017-2031
Figure 15: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Immunology, 2017-2031
Figure 16: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Rare Diseases, 2017-2031
Figure 17: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Neurological Diseases, 2017-2031
Figure 18: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Others, 2017-2031
Figure 19: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 20: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 21: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Flow Cytometry, 2017-2031
Figure 22: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Image-based Cytometry/Microscopy, 2017-2031
Figure 23: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Biochemical Assays, 2017-2031
Figure 24: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Mass Spectrometry, 2017-2031
Figure 25: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace, 2022 and 2031
Figure 26: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 27: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Target Identification, 2017-2031
Figure 28: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Hit Generation & Lead Identification, 2017-2031
Figure 29: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Lead Optimization, 2017-2031
Figure 30: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by In Vitro Preclinical Studies, 2017-2031
Figure 31: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by In Vivo Preclinical Studies, 2017-2031
Figure 32: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Clinical Studies, 2017-2031
Figure 33: Global Cell Analysis Market Value Share Analysis, by Region, 2022 and 2031
Figure 34: Global Cell Analysis Market Attractiveness Analysis, by Region, 2023-2031
Figure 35: U.S. Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 36: U.S. Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 37: U.S. Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 38: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 39: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 40: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 41: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 42: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 43: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 44: Europe Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 45: Europe Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 46: Europe Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 47: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 48: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 49: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 50: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 51: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 52: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 53: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 54: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 55: China Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 56: China Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 57: China Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 58: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 59: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 60: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 61: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 62: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 63: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 64: Rest of the World Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 65: Rest of the World Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 66: Rest of the World Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 67: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 68: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 69: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
Figure 70: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
Figure 71: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 72: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031

Cell Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Description

Table of Contents

List of Tables

Cell Analysis Market - Scope of Report

Key Questions Answered in Global Cell Analysis Market Report:

Cell Analysis Market - Research Objectives and Research Approach

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Market Overview

4. Global Cell Analysis Market Analysis and Forecast, by End-user

5. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Therapeutic Area

6. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Technology

7. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace

8. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Country/Region

9. U.S. Cell Analysis Market Analysis and Forecast

10. Europe Cell Analysis Market Analysis and Forecast

11. China Cell Analysis Market Analysis and Forecast

12. Rest of the World Cell Analysis Market Analysis and Forecast

List of Tables

List of Figures